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ABSTRACT
JAK2 mutations are rare in de novo acute myeloid leukemia (AML), and JAK2-mutated acute myeloid leukemia (AML) 
patients usually have a previous history of myeloproliferative neoplasms (MPNs). Current advances in laboratory techniques, 
such as single nucleotide polymorphism array (SNPa) and next-generation sequencing (NGS), have facilitated new insight 
into the molecular basis of hematologic diseases. Herein, we present two cases of JAK2-mutated AML in which both 
SNPa and NGS methods added valuable information. Both cases had leukemogenic collaboration, namely, copy-neutral 
loss of heterozygosity (CN-LOH), detected on chromosome 9. One of the cases exhibited both JAK2 and IDH2 mutations, 
most likely having originated as an MPN with leukemic transformation, while the other case was classified as a de novo 
AML with JAK2, CEBPA, and FLT3 mutations. 
Keywords 
Cytogenetics; Leukemia, Myeloid, Acute; Polymorphism, Single Nucleotide; Sequence Analysis, DNA
INTRODUCTION
Myeloproliferative neoplasms (MPNs) are clonal 
disorders of hematopoietic stem cells with increased 
proliferation of myeloid cells and effective maturation, 
leading to peripheral blood leukocytosis and excess 
erythrocytes or platelets.1 According to the World 
Health Organization (WHO) 2016 revision of the 
classification of myeloid neoplasms and acute leukemia, 
MPNs are subdivided into (i) chronic myeloid leukemia 
(BCR-ABL1–positive); (ii) chronic neutrophilic leukemia; 
(iii) polycythemia vera; (iv) primary myelofibrosis; 
(v) essential thrombocythemia; (vi) chronic eosinophilic 
leukemia; and (vii) unclassifiable myeloproliferative 
neoplasm.2 The final evolution of MPNs involves 
progression to fibrosis or leukemic transformation. 
Acute myeloid leukemia (AML) following MPNs is 
characterized by 20% or more blasts being present 
in the bone marrow (BM) or peripheral blood (PB).3 
MPN patients who develop AML have a poor prognosis, 
with a median survival of fewer than 6 months.4 
Leukemic transformation occurs in 1%, 4% and 20% 
of patients with essential thrombocythemia (ET), 
polycythemia vera (PV) and primary myelofibrosis (PM), 
respectively, over a 10-year period.5
Mutations in JAK2 have been identified in the 
majority of patients with PV, ET, and PM, underscoring 
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the importance of constitutive activation of JAK2 
signaling caused by mutations.6 Genetic studies of 
paired samples before and after AML transformation 
suggest that there are at least two distinct routes for 
leukemic transformation. Patients who exhibit the JAK2 
mutation in MPNs progress to AML, suggesting that 
this mutation might be associated with the acquisition 
of additional genetic alterations. In contrast, patients 
who harbor the JAK2 mutation in their MPNs have no 
evidence of the mutation in leukemic blasts post-MPN 
AML.6,7 It is important to highlight that, despite the 
cooccurrence of JAK2 mutations with other genetic 
alterations, JAK2 mutations have rarely been reported 
in de novo AML (<5%).8,9
Cytogenetic and molecular cytogenetic techniques 
combined may provide a comprehensive analysis of 
chromosomal aberrations. Advances in laboratory 
techniques, such as single nucleotide polymorphism 
array (SNPa), a molecular cytogenetic method, and 
high-throughput sequencing, have facilitated new 
insight into the molecular basis of hematologic 
diseases. SNPa is a sensitive technique used to 
perform high-resolution genome-wide DNA copy 
number analysis and to detect copy-neutral loss of 
heterozygosity (CN-LOH). Next-generation sequencing 
(NGS) is capable of detecting single nucleotide 
variants (SNVs) or small insertions and deletions that 
have recently been shown as important molecular 
phenomena in AML.10 To substantiate this idea, we 
describe two JAK2-mutated AML cases for which both 
SNPa and NGS added valuable information.
METHODS
Patients
The patients described in this report were seen 
for follow up at the Hospital São Paulo of the Federal 
University of São Paulo, São Paulo, Brazil. The Ethics 
Committee of the institution approved the study, 
and written informed consent was obtained from all 
patients (CAAE 00547512.5.0000.5505).
Conventional Cytogenetics
Karyotypes were made from BM samples using 
standard methods, and aberrations were described 
according to the International System for Human 
Cytogenetic Nomenclature (ISCN) 2016.11
Single Nucleotide Polymorphism Array
SNPa was performed on total BM (cases 1 and 2) 
and buccal cells (only case 1) samples. Two hundred 
and fifty nanograms of DNA were extracted and 
digested, amplified, purified, fragmented, labeled and 
hybridized using the Affymetrix CytoScan HD Array. 
CEL files were created using the GeneChip System 
3000 7G according to the manufacturer’s instructions. 
CEL files were analyzed using Chromosome Analysis 
Suite v3.0 (ChAS) software. Regions of copy number 
variations (CNVs) larger than 1 Mb and CN-LOH 
larger than 10 Mb identified by the ChAS Software 
or detected by visual inspection, regardless of gene 
content, are considered true aberrations, with the 
exception of those known to be normal genomic 
variants (present in the Genomic Variants Database 
[http://projects.tcag.ca/variation]) or identified in 
constitutional (buccal cells) SNPa analysis.10 Aberrations 
identified by SNPa were described according to the 
ISCN 2016.
Next-Generation Sequencing
Total BM was used for DNA extraction. A 19-gene 
panel was screened using the Ion AmpliSeq AML 
Research Panel (Thermo Fisher). Reads were mapped 
to the HG19 reference human genome, and 
alignment results were analyzed using CLC Genomics 
Workbench software.10 FLT3-ITD was tested in 
addition to the gene panel by PCR and capillary 
electrophoresis using the following primers: forward 
5’−6FAM- tgcctattcctaactgactcatc-3’ and reverse 
5’- tctttgttgctgtccttccac-3’.
CASE REPORTS
Case 1: A 66-year-old female patient was referred 
to the Hematology service for investigation of 
polyglobulia (hemoglobin 17.0 g/dL and hematocrit 
53.4%) associated with weight loss (18 kg over the 
last six months). However, admission lab tests showed 
hemoglobin of 9.4 g/dL, hematocrit of 33.4%, WBC 
count of 47.8 × 109/L (with 22% blasts) and platelet 
counts of 119.0 × 109/L. Bone marrow aspirate smear 
revealed 20% of blasts, and multiparametric flow 
cytometry immunophenotyping was compatible 
with AML (Positive: CD45 moderate, CD34, HLA-DR, 
Noronha TR, Mitne-Neto M, Chauffaille ML
3-7Autops Case Rep (São Paulo). 2019;9(2):e2018084
CD117, CD33 heterogeneous, CD13 heterogeneous, 
CD11b partial, CD64 partial heterogeneous, CD36 
partial, CD7 partial. Negative: CD14, CD65, CD41, 
CD2, CD4, CD56, CD19, CD10). The bone marrow 
karyotype is as follows: 48,XX,+8,+21[11]/46,XX[1]. 
SNPa results are as follows: arr[hg19] (8)x2-3; arr[hg19] 
(21)x2-3; arr[hg19] 9p24.3p13.3(192128_35098008) 
hmz (Figure 1). NGS analysis revealed IDH2 R140Q and 
JAK2 V617F mutations. The patient was on chronic 
osteomyelitis treatment prior to initiating chemotherapy 
and died one month after admission due to infection.
Case 2: A 77-year-old female patient was admitted 
to hematology service with complaints of fatigue 
and easy bruising. Lab tests on admission showed 
hemoglobin of 10.3 g/dL, WBC count of 99.9 × 109/L 
(with 45% blasts) and platelet counts of 23.0 × 109/L. 
Bone marrow aspirate, showing 40% blasts and 
multiparametric flow cytometry immunophenotyping, 
was compatible with AML (Positive: CD34, CD117, 
CD13, CD45 moderate, CD33, HLA-DR, CD64, CD7. 
Negative: CD11b, CD10, CD19, CD15, CD36, CD14, 
CD65, CD2, CD56). The bone marrow karyotype did 
not present metaphases. SNPa results are as follows: 
arr[hg19] 8q23.1q24.12(107621735_119398978)×1; 
arr[hg19] 9p24.3p13.1(192128_40087758) hmz; 
arr[hg19] 11p15.5p11.2(198509_47404314) hmz 
(mosaic) (Figure 2). NGS results revealed mutations in 
FLT3-ITD, CEBPA E309_T310insE and JAK2 V617F. The patient 
was on conventional chemotherapy treatment and 
died three months after admission due to infection.
DISCUSSION
The two cases presented herein were classified 
as AML, one of which had a previous history of 
polyglobulia and weight loss (case 1), while the other 
had become recently symptomatic (case 2). Based on 
the clinical history, one may interpret the first case 
as leukemic transformation of a myeloproliferative 
neoplasm and the second as de novo AML.
Which tests could confirm the above-mentioned 
hypotheses: Conventional cytogenetics (karyotype), 
molecular cytogenetics (SNPa) or molecular tests 
(NGS)?
Cytogenetic abnormalities identified by karyotype 
allow the detection of clonal abnormalities, classifying 
cases into favorable, intermediate or unfavorable 
prognosis. Karyotype remains one of the most 
powerful predictors of outcome in AML.12 However, 
approximately 50% of AML cases present a normal 
karyotype or present noninformative results, requiring 
other tests to better characterize the disease.10
Figure 1. Genomic alterations detected by SNPa (Affymetrix CytoScan HD array) in case 1. a – Mosaic gain of one 
entire chromosome 8 (CN: 2.57). b – Red box showing CN-LOH in 9p24.3p13.3. The JAK2 gene is located in this 
region. c – Mosaic gain of chromosome 21 (CN: 2.54).
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Our first case presented a hyperdiploid karyotype, 
(trisomies 8 and 21), an aberration observed in 0.7% 
of AMLs,13 allowing no additional clarification to the 
posed question. However, it allowed the classification 
of this case as intermediate risk by the European 
Leukemia Net genetic classification,14 although this is a 
conceptually a high-risk disease as it fits into the “AML 
with myelodysplasia-related changes” (post-MPN 
AML). For case 2, the karyotype was noninformative, 
and in this condition, risk stratification could not be 
correctly interpreted.
SNPa is a complementary tool to karyotype, and 
may be applied for the evaluation of chromosomal 
losses, gains and CN-LOH. Combining SNPa with 
karyotype increases the detection rate of abnormalities 
in 28%.15 Advances in high-throughput sequencing 
techniques have facilitated new insights into the 
molecular basis of AML.12,16 Indeed, each test has 
distinct performances characteristics, with variability 
in the detection rate being defined by the type of 
genomic alteration (Table 1).
SNPa confirmed the karyotype results in case 1 
and added new information in both cases: CN-LOH 
on chromosome 9 (cases 1 and 2), CN-LOH on 
chromosome 11 (case 2) and partial deletion of 
chromosome 8 (case 2). CN-LOH indicates that 
an individual possesses two identical copies of 
one chromosome or chromosome region, i.e., this 
abnormality represents an important mechanism by 
which point mutations and other micro lesions can be 
Figure 2. Genomic alterations detected by SNPa (Affymetrix CytoScan HD array) in case 2. a – Red box showing 
deletion in 8q23.1q24.12 (CN: 1.00). b – Red box showing CN-LOH in 9p24.3p13.1. The JAK2 gene is located in 
this region. c – Red box showing mosaic CN-LOH in 11p15.5p11.2.
Table 1. Technique comparison for identifying genetic abnormalities
Technique
Characteristics
Resolution Gain and Loss Translocation CN-LOH SNVs/INDELs
Karyotype 5Mb Yes Yes No No
SNPa <1Mb Yes No Yes No
NGS 1Bp Yes* No No Yes
SNPa: Affymetrix CytoScan™ HD. NGS: Ion AmpliSeq™ AML Research Panel. *SNVs (Single Nucleotide Variants) / INDELs 
(Insertions and Deletions <50 base pairs).
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established in a homozygous state.17 JAK2 and FLT3 
mutations share a common mechanism that confers 
augmented reactive oxygen species, which induce 
DNA damage, resulting in homologous recombination 
events that initiate CN-LOH.18
NGS identified mutations in both cases, two in 
case 1 and three in case 2. The JAK2 V617F mutation 
was identified in both cases. Case 1 presented 72.5% 
allelic frequency, and case 2 exhibited 94.3% allelic 
frequency. These values are compatible with a CN-LOH 
on chromosome 9 detected by SNPa, where the JAK2 
is gene located. In MPNs, the high JAK2 V617F allele 
burden in PV represents a risk factor for progression to 
myelofibrosis. In contrast, high JAK2 V617F allele burden 
is not significantly related to leukemic transformation.19 
The JAK2 mutation constitutively activates the 
JAK/STAT signaling pathway, but the prognostic 
implications of this alteration remain unclear.20
Regarding the other mutations, IDH2 (case 1) 
is involved in DNA methylation, and the relationship 
of this mutation with prognosis is still uncertain.21 
However, some groups have identified the IDH2 
mutation in a subset of patients with MPN who 
underwent leukemic transformation.22,23 In addition, 
combined expression of JAK2 V617F and IDH2 R140Q 
induces MPN progression, alters stem/progenitor cell 
function and impairs differentiation in mice.24
The CEBPA mutation is involved in the development 
of myeloid progenitors into differentiated neutrophils. 
Previous studies suggest that monoallelic mutations 
in CEBPA are prognostically neutral, whereas biallelic 
mutations in trans are associated with a favorable 
prognosis in cytogenetically normal AML.25 FLT3-ITD 
constitutively activate tyrosine kinase by interfering 
with the autoinhibitory function of the juxtamembrane 
domain, leading to enhanced RAS, MAPK, and STAT5 
signaling. Mutations in this gene are associated with 
worse prognosis.25
JAK2 mutations are rare in de novo AML, and 
AML patients with JAK2 mutations usually have a 
history of an antecedent MPN. The most common 
mutations observed in de novo AML, including NPM1, 
DNMT3A, and FLT3, are largely absent from AMLs 
that occur following an MPN.6 Despite the infrequent 
incidence of JAK2 mutation in AML, mutated JAK2 
could be therapeutically targeted in some cases with 
JAK2 mutations.8
SNPa and NGS added valuable information to 
these analyses, as both cases exhibited leukemogenic 
collaboration of the detected mutations: one had 
JAK2 and IDH2 mutations, being most likely an MPN 
with leukemic transformation, while the other could 
be a de novo AML with JAK2, CEBPA, and FLT3 
mutations.
In summary, the present work supports the 
use of both SNPa and NGS as important tools for 
patients with AML, offering insights into the molecular 
pathogenesis and indicating that different mutation 
combinations and cytogenetic results could further 
stratify prognosis.
The authors retain an informed consent signed 
by the patients, and this manuscript is in accordance 
with the Institutional Ethics Committee.
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